A study of Trichostatin-A for hematologic malignancies

Trial Profile

A study of Trichostatin-A for hematologic malignancies

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Trichostatin A (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Feb 2017 New trial record
    • 15 Feb 2017 According to a Vanda Pharmaceuticals media release, the company expects to submit an investigational new drug application to the FDA in mid 2017 for trichostatin A.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top